Connect with us

Life Sciences

Genomic Vision Joins France BioLead to Advance Innovation and Production of Biopharmaceuticals in France

Participation in France BioLead reflects the Company’s growing focus on innovation for bioproduction in line with its strategy to accelerate advancements…

Published

on

This article was originally published by AITHORITY
Genomic Vision Joins France BioLead to Advance Innovation and Production of Biopharmaceuticals in France
  • Participation in France BioLead reflects the Company’s growing focus on innovation for bioproduction in line with its strategy to accelerate advancements in genomics

  • DNA combing technology is a unique tool for characterization of transformed cells used for quality control throughout the bioproduction cycle

Genomic Vision, a Euronext-listed biotechnology company that develops products and services dedicated to the analyses and control of changes in the genome, is pleased to announce that it has joined France BioLead.

AiThority Interview Insights: AiThority Interview with Malcolm Koh, Director, CX Practice at Zendesk

The France BioLead Association was officially launched in December 2022 by the French government and 15 founding members, players from all the biomanufacturing value chains. Its mission is to structure, steer, support, animate and promote the French biomanufacturing industry and its players. Its purpose is to support the development of the various technological value chains of a sovereign and innovative French biomanufacturing industry throughout the life cycle of the biomedical product, to ensure the availability of biomedical products for patients, and to build an attractive and recognized industry, particularly internationally.

Its three major objectives for 2030 are: to double the proportion of biomedical products produced in France, to double the number of jobs in the sector (from 10,000 to 20,000), and to enable the emergence of at least one new unicorn and five new biotech SMEs.

Read More about AiThority InterviewAiThority Interview with Ben Plomion, Chief Marketing Officer at Dibbs

Aaron Bensimon, Chief Executive Officer of Genomic Vision commented: “As we increase our focus on bioproduction, a part of our new strategic orientation, Genomic Vision is proud to be part of the first cohort of members of the France BioLead association, aiming to accelerate the development of the French bioproduction sector. Our DNA combing technology is a valuable tool for characterization of transformed cells used for quality control throughout the bioproduction cycle. We will work within France BioLead to establish the French bioproduction sector as a global leader along with our fellow members, including many international players. Lionel Seltz, our CFO, will coordinate the working group for financing topics.”

As part of its membership, Genomic Vision will have access to France BioLead’s network of experts and industry leaders, as well as opportunities to participate in a range of events and initiatives, including industry conferences and seminars.

 Latest AiThority Interview Insights : AiThority Interview with Ruairi Adam, Director of Global Transformation at Majorel

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Genomic Vision Joins France BioLead to Advance Innovation and Production of Biopharmaceuticals in France appeared first on AiThority.


Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending